Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income also saw a 3% decrease. For the f...

Cipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also...

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...

Cipla's global CEO Umang Vohra will step down in March 2026. Achin Gupta, currently global COO, will take over as the new MD and GCEO from ...

"We're all human beings, we get distracted with what happens, because of this and that distraction creates difficulties for us in the way w...

"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...

"This approval is a significant step for our US business and is in line with our aspiration to continue growth in our complex product pipel...

The board of directors has considered and approved the re-appointment of Umang Vohra, Managing Director, designated as 'Managing Director a...

In an interview with Suman Layak, Vohra explains his strategy of taking Cipla products to global markets.

The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.

As per Cipla's co-exclusive agreement with SII, the former will market the vaccine for adults while the latter will market it for adults an...

Until recently, Kedar was Vice President, Global Generics Finance and Head of Investor Relations in Dr Reddy's Laboratories, Cipla said in ...

Drug firm Cipla will invest around Rand 1.3 billion (over Rs 590 crore) to launch a manufacturing facility in South Africa for the producti...

The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.

Cipla (EU) Ltd, UK, a wholly-owned subsidiary of Mumbai-based drug firm, has inked the JV agreement with the Moroccan entities.

Sell Cipla with stoploss of Rs 421 and for target of Rs 402.

Cipla Ltd is a 'BUY' call with a target of Rs 440 and a stop loss of Rs 406.